COVID-19 Rapid LFI Assay

About New Horizons Diagnostics

New Horizons Diagnostics is a long-established, privately-held biotech firm with a dual focus on rapid diagnostic tests and novel therapeutic platforms. The company possesses a deep historical track record of innovation, including pioneering colloidal gold assays and developing tests for NASA and the U.S. military. Its current strategy involves leveraging core technologies in immunoassays and bacteriophage lytic enzymes to address critical needs in biodefense, food safety, and infectious disease, supported by active contracts with agencies like the Defense Threat Reduction Agency (DTRA).

Therapeutic Areas

Other COVID-19 Detection Drugs